In a nutshell This phase 2 study will investigate Tavokinogene Telseplasmid Electroporation (TTE) in combination with pembrolizumab (Keytruda) in advanced or not suitable for surgery triple-negative breast cancer (TNBC). The main outcome will be the objective response rate (ORR). This trial is recruiting in the United States and...
Read MoreCurrent stage-Stage III Posts on Medivizor
Searching for patients with colorectal cancer to test this new treatment combination
In a nutshell This phase 2 trial is examining the effectiveness and safety of navarixin (MK-7123) in combination with pembrolizumab (Keytruda) in patients with colorectal cancer (CRC). The main outcome to be measured will be the objective response rate (ORR; tumor shrinkage or disappearance). The details A treatment option for patients with...
Read MoreSearching for patients with lung cancer that cannot be operated on to test durvalumab after chemotherapy and radiation
In a nutshell This phase 2 trial will investigate the safety and effectiveness of durvalumab (Imfinzi) in patients with stage III non-small cell lung cancer (NSCLC). The main outcomes will be the number of treatment-related adverse events (TRAEs) and progression-free survival (PFS). The details Non-small cell lung cancer (NSCLC)...
Read MoreLong-term outcomes for dabrafenib plus trametinib treatment for metastatic melanoma.
In a nutshell This study wanted to find out how well patients with advanced melanoma with mutations (abnormal genes) survive when treated with dabrafenib (Tafinlar) and trametinib (Mekinist) combination. The study found that long term, patients survived moderately well with this treatment. Some background Advanced melanoma can be hard to treat. In...
Read MoreLooking patients with advanced cancer to test a new immunotherapy combination
In a nutshell This phase 1/2 trial will investigate BMS-986253, an experimental drug, in combination with nivolumab (Opdivo) to treat advanced cancer. The main outcomes will be the occurrence of side effects and tumor response. The details Advanced cancers have limited treatment options. New drugs are in development to improve patient prognosis. These...
Read MoreLooking patients with advanced cancer to test a new immunotherapy combination
In a nutshell This phase 1/2 trial will investigate BMS-986253, an experimental drug, in combination with nivolumab (Opdivo) to treat advanced cancer. The main outcomes will be the occurrence of side effects and tumor response. The details Advanced cancers have limited treatment options. New drugs are in development to improve patient prognosis. These...
Read MoreLooking patients with advanced cancer to test a new immunotherapy combination
In a nutshell This phase 1/2 trial will investigate BMS-986253, an experimental drug, in combination with nivolumab (Opdivo) to treat advanced cancer. The main outcomes will be the occurrence of side effects and tumor response. The details Advanced cancers have limited treatment options. New drugs are in development to improve patient prognosis. These...
Read MoreSearching for patients with melanoma to test this new melanoma vaccine with or without immunotherapy
In a nutshell This trial is examining the effectiveness and safety of 6MPH, a melanoma vaccine with adjuvants and a CDX-1127 monoclonal antibody in patients with melanoma. The main outcomes to be measured will be side effects and the response of the immune system. This trial is recruiting in Virginia, United States. The details A treatment option...
Read MoreSearching for patients with advanced non-small cell lung cancer to test this new treatment option
In a nutshell This phase 1/2 trial is examining the effectiveness and safety of KY1044 alone and in combination with atezolizumab (Tecentriq) for patients with advanced cancers who are not suitable for any other treatment or have failed all other treatment options. The main outcomes to be measured will be the occurrence and severity of side effects and...
Read MoreSearching for patients with advanced melanoma to test this new treatment option
In a nutshell This phase 1/2 trial is examining the effectiveness and safety of KY1044 alone and in combination with atezolizumab (Tecentriq) for patients with advanced cancers who are not suitable for any other treatment or have failed all other treatment options. The main outcomes to be measured will be the occurrence and...
Read MoreSearching for patients with advanced breast cancer to test a new T-cell treatment
In a nutshell This phase 2 trial will investigate the effectiveness of genetically-engineered cell treatment (GECT) in advanced cancer. The main outcome will be the response to treatment. This trial is recruiting at the National Cancer Institute, Maryland, US. The details There are limited treatment options for advanced cancer. One...
Read MoreSearching for patients with triple negative breast cancer to test this new treatment combination
In a nutshell This trial is examining the safety and effectiveness of combination therapy with pembrolizumab (Keytruda) and lenvatinib (Lenvima) for triple negative breast cancer (TNBC) and other solid tumors. The main outcome to be measured will be the objective response rate (ORR; the percentage of participants who have complete...
Read More
